FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... September 13, 2024 Reducing the Cancer Burden: Future Directions for NCI’s Cancer Control Research December 19, 2022 Radionuclide Therapy Could Be A Viable Treatment For Early-Stage Breast Cancer,... February 20, 2020 Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers July 7, 2026 Load more HOT NEWS Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors Blind Customer Surprised With Sweet Message In Braille For Her Birthday Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with... Women in science: Cancer research pioneers – part 1
